University of Patras
Μελέτη του υποδοχέα anaplastic lymphoma kinase στην αγγειογένεση, ως στόχου για θεραπευτικές προσεγγίσεις
Abstract
dc:descriptionAngiogenesis, the process of creating new blood vessels, plays an important role in the normal functioning of the body and cancer. Angiogenesis inhibitors are used as anticancer therapy, but some patients develop resistance or disease progression. A factor that has been studied in recent years and appears to play an important regulatory role in the process of normal and cancer angiogenesis is pleiotrophin (PTN), through its receptor with tyrosine phosphatase activity PTPRZ1. The pathway activated downstream of PTPRZ1 is only partially elucidated and it may involve the activation of the ALK receptor. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is being studied as a therapeutic target in various types of cancer. ALK tyrosine kinase inhibitors, such as crizotinib, are already used in the treatment of non-small cell lung cancer, when specific ALK chimeric proteins are expressed, while recently ALK is also being studied as a therapeutic target for glioblastoma. The aim of this thesis is to investigate the role of ALK in angiogenesis, as a target for therapeutic approaches. For this purpose, studies were performed on endothelial cells derived from human umbilical vein or from lung capillaries of knockout mice for the PTPRZ1 gene (Ptptrz1-/-) as well as their wild-type counterparts. In addition, the role of ALK was studied in normal angiogenesis in vivo using the chick embryo chorioallantoic membrane (CAM) model, as well as in cancer angiogenesis using the urethane chemical lung carcinogenesis model. Pharmacological inhibitors of the ALK tyrosine kinase, such as crizotinib, were found to inhibit the increased angiogenic activities observed in Ptprz1-/- LMVEC endothelial cells or HUVECs following PTPRZ1 tyrosine phosphatase inhibition. They also inhibit VEGFA165- or PTN-induced endothelial cell functions such as proliferation, migration, Akt kinase activation and mitochondrial elongation. Crizotinib also inhibits the mitochondrial elongation observed in Ptprz1-/- LMVECs compared to Ptprz1+/+ LMVECs. PTN also induces mitochondrial elongation in HUVEC cells and crizotinib inhibits this effect. In conclusion, these results suggest that pharmacological inhibitors of ALK, such as crizotinib, inhibit the VEGFA and PTN induced angiogenic activities mediated by the PTPRZ1 receptor. However, it was not possible to detect ALK expression in Ptprz1-/- and Ptprz1+/+ LMVECs, nor its activation induced by VEGFA165 or PTN in any of the endothelial cell types studied. Therefore, further future studies and better pharmacological or biochemical tools are needed to elucidate any role of ALK in the direct regulation of angiogenesis.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntenekou, Despoina
- Ντενέκου, Δέσποινα
Subjects
dc:subject × 14- Αγγειογένεση
- Κινάση αναπλαστικού λεμφώματος
- Ενδοθηλιακά κύτταρα
- Αναστολείς κινάσης τυροσίνης
- Anaplastic lymphoma kinase
- Angiogenesis
- Endothelial cells
- Tyrosine kinase inhibitors
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54930